JPRN-UMIN000003135已完成2 期
Randomized phase II study of bortezomib plus dexamethasone (BD) versus thalidomide plus dexamethasone (TD) for relapsed or refractory multiple myeloma (JCOG0904, r II BD vs TD for MM) - Randomized phase II study of bortezomib plus dexamethasone (BD) versus thalidomide plus dexamethasone (TD) for relapsed or refractory multiple myeloma (JCOG0904, r II BD vs TD for MM)
Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 44 人开始时间: 2010年2月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) synchronous or metachronous malignancy 2) active infection 3) febrile over 38oC 4) pregnant or nursing women 5) psychological disturbance 6) continued treatment with steroids for non-malignant disorders 7) insulin-dependent or uncontrollable diabetes mellitus 8) uncontrollable hypertension 9) HBs-Ag positive or HCV-Ab positive 10) HIV-Ab positive 11) interstitial pneoumonia, pulmonary fibrosis, severe pulmonary edema, or severe pleural effusion on chest CT 12) grade 2 or higher peripheral neuropathy, or grade 1 or higher neuralgia 13) glaucoma 14) allergic history to borate or mannitol
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Relapsed or Refractory Multiple Myeloma trial - with orwithout Elotuzumab.Relapsed or Refractory Multiple MyelomaMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002695-16-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO150
进行中（未招募）
1 期
A Phase 2 Relapsed or Refractory Multiple Myeloma trial - with or without Elotuzumab.Relapsed or Refractory Multiple MyelomaMedDRA version: 14.0Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002695-16-ESBristol-Myers Squibb International Corporation150
进行中（未招募）
不适用
Phase II Study of combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom?s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - NDWaldenstrom macroglobulinemiaMedDRA version: 9.1Level: LLTClassification code 10047714Term: Von Waldenstrom macroglobulinaemiaEUCTR2006-003563-31-ITE.M.N. - EUROPEAN MYELOMA NETWORK61
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Networkimmunocytomalymphoplasmacytic lymphomaWaldenstroms Macroglobulinemia10018865NL-OMON30654Academisch Medisch Centrum5
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - protocole BDRMacroglobulinémie de Waldenström au moment de l’initiation du traitement de 1e ligne.EUCTR2006-003563-31-FRCentre Hospitalier de Lens61